Stock Analysis
RPG Life Sciences Second Quarter 2025 Earnings: EPS: ₹2.54 (vs ₹15.64 in 2Q 2024)
RPG Life Sciences (NSE:RPGLIFE) Second Quarter 2025 Results
Key Financial Results
- Revenue: ₹1.74b (up 13% from 2Q 2024).
- Net income: ₹42.0m (down 84% from 2Q 2024).
- Profit margin: 2.4% (down from 17% in 2Q 2024).
- EPS: ₹2.54 (down from ₹15.64 in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
RPG Life Sciences shares are down 5.1% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with RPG Life Sciences, and understanding them should be part of your investment process.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:RPGLIFE
RPG Life Sciences
An integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.
